Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Jefferson Research
$20.00
Provider: Sadif Analytics Prime
$10.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline and Genmab announce positive interim result for phase III study of Ofatumumab as maintenance therapy for relapsed CLL


Thursday, 31 Jul 2014 02:52pm EDT 

Glaxosmithkline plc:Says the company and Genmab A/S announced that an Independent Data Monitoring Committee (IDMC) interim analysis of a Phase III study, PROLONG (OMB 112517), reached the predefined significance level for efficacy (p<=0.001).Says the interim analysis demonstrated that treatment with ofatumumab (Arzerra(tm)) met the primary endpoint of improving progression free survival (PFS).Says the study evaluated ofatumumab maintenance therapy versus no further treatment (observation) in patients with relapsed chronic lymphocytic leukemia (CLL) who responded to treatment at relapse.Ofatumumab is being developed under a co-development and collaboration agreement between Genmab and GSK.